in mammals , most genes are represented by two functional copies . the present invention discloses for the first time the result of inactivation of one copy of the pparδ ( β ) gene in mice through a gene knockout approach . pparδ ( β ) heterozygous knockout mutant mice with one gene copy inactivated , exhibit no abnormal behavioral properties . they also show normal body weight as compared to wild type littermates with two gene copies when fed a regular low fat ( 4 - 6 %) chow diet . however , when fed a diet rich in fat ( 40 %) and sucrose ( 40 %) the heterozygous knockout mice show resistance to diet - induced obesity as compared to wild type littermate control mice ( fig1 ). as illustrated in fig1 pparδ ( β ) heterozygous knockout mice gained body weight at a decreased rate relative to pparδ ( β ) wild type mice . the heterozygous knockout mice have reduced body mass index ( bmi ) values , which is a measure of body fat and obesity , without significant changes in body length ( fig2 ). anatomical analysis shows a substantial reduction in the size of the abdominal fat depot in heterozygous knockout mice relative to wild - type mice ( fig2 ). in mammals , the size of the abdominal fat depot is frequently associated with the risk for the development of insulin resistance and type 2 diabetes . in accordance with this , blood plasma chemistry analysis shows significantly reduced levels of both fasted and ad libitum fed insulin in heterozygous pparδ ( β ) knockout mice as compared to wild type animals ( table 1 ). this finding is interpreted as an indication of increased insulin sensitivity in heterozygous pparδ ( β ) knockout mice because they are able to maintain wild type levels of both fasting and fed glucose with substantially reduced levels of insulin ( table 1 , below ). another important finding in heterozygous pparδ ( β ) knockout mice is that the body weight reduction is achieved without any significant change in blood plasma levels of free fatty acids , triglycerides or cholesterol during the course of the study ( table 1 ). * statistically significant difference , p & lt ; 0 . 05 the data in this table demonstrates that pparδ ( β ) heterozygous knockout mice show improved insulin sensitivity ( i . e . reduced levels of fasting and fed insulin while maintaining glucose levels equal or less than that of wild type mice ) relative to wild - type mice . in addition the data shows that there is no significant change in plasma lipid levels including free fatty acids , triglycerides and or cholesterol . in this study blood was collected from the tail vein after 16 - hour fasting and after over night ad libitum feeding . plasma , glucose , insulin , cholesterol , triglycerides and nefa values were determined using standard methodologies . the herein described invention therefore discloses that pparδ ( β ) potentiates an increase in abdominal fat , obesity and insulin resistance ( high insulin ) when the animals are fed a diet high in fat and sucrose . however , when one copy of pparδ ( β ) was inactivated as in heterozygous pparδ ( β ) knockout mice , these animals show : ( 1 ) resistance to diet - induced obesity , ( 2 ) reduced abdominal fat pad mass , and ( 3 ) improvement in insulin sensitivity ( reduced levels of insulin ). significantly , weight loss and reduction in abdominal fat pad mass are achieved in heterozygous pparδ ( β ) knockout mice without any significant changes in blood lipid profile . the present invention therefore presents a genetic proof of principle for a method for treating obesity and the often associated insulin resistance and type 2 diabetes through some degree of inactivation of pparδ ( β ). the present invention provides a method for treating obesity , insulin resistance and type 2 diabetes in mammals through administration of a pharmacological composition containing an agent which may have the ability to reduce : ( 1 ) the activity of pparδ ( β ) protein , or ( 2 ) expression of the pparδ ( β ) gene , or ( 3 ) expression of pparδ ( β ) regulated target genes ( or any combination of the above ). the inactivation of pparδ ( β ) may be achieved through : ( 1 ) direct binding of a pharmacological agent ( a pparδ ( β ) antagonist ) to the pparδ ( β ) receptor and reduction of its transcriptional activation potential , or ( 2 ) through disrupting a productive association of pparδ ( β ) with its obligate heterodimeric binding partner rxrα , or ( 3 ) downregulating the expression of the pparδ ( β ) gene , or ( 4 ) selectively modulating its activity in a tissue through preventing the binding of a co - activator , or promoting the binding of a co - repressor , or any combination of the above . the resulting product of these changes may include any combination of ( but are not limited to ): ( 1 ) prevention of weight gain , ( 2 ) weight loss and ( 3 ) improvement in insulin resistance . the present invention also provides a treatment method involving the use of a combination of a pparδ ( β ) antagonist , anti - diabetic agents such as but not limited to metformin and / or a sulfonylurea to control insulin resistance and type 2 diabetes in obese insulin resistant / type 2 diabetes patients . since most obese diabetic individuals also suffer from dyslipidemia and cardiovascular disease , this invention also proposes that a combination of a pparδ ( β ) antagonist , an anti diabetic agent and a lipid lowering agent such as a pparα agonist ( such as , but not limited to , fenofibrate and gemfibrozil ) and a hmg - coa reductase inhibitor ( such as , but not limited to , pravastatin , lovastatin , simvastatin and atorvastatin ) may be used to reduce hyperlipidemia and cardiovascular diseases . this invention also provides methods for screening and identification of compounds that bind to and / or regulate pparδ ( β ). the pparδ ( β ) ligand binding domain ( lbd ) from a mammalian species including human and / or a non - mammalian species such as frog ( xenopus ), is used for screening for compounds that bind to the lbd ( schmidt et al , mol . endocrinology , 6 : 1634 - 1641 , 1992 ; evans et al ., sequence xr - 4 in u . s . pat . no . 5571696 , 1996 ; berger et al . j . biol . chem ., 274 : 6718 - 6725 , 1999 ). in this in vitro binding assay , the affinity of a test compound to pparδ ( β ) is determined by its ability to competitively inhibit binding of a known ligand ( as described in ref leibowitz and berger wo 97 / 28149 1997 ; berger et al . j . biol . chem ., 274 : 6718 - 6725 , 1999 .) to pparδ ( β ). in the cell based assay , a suitable mammalian , insect , or yeast cell line is co - transfected with a chimeric gal4 / pparδ or gr / pparδ receptors and gal4 / seap , gal - 4 / β - lactamase and a gal - 4 / luciferase or gr / seap , gr / β - lactamase , gr / luciferase or other suitable reporter gene dna constructs ( sadowski and ptashne , nuc . acid . res . 17 : 7539 , 1989 ; kliewer et al ., nature , 358 : 771 - 774 , 1992 ; schmidt et al , mol . endocrinology , 6 : 1634 - 1641 , 1992 ; lehmann et al ., j . biol . chem ., 270 : 12953 - 12956 , 1995 ; tugwood et al ., arch . toxicol ., 72 : 169 - 177 , 1998 ; berger et al . j . biol . chem ., 274 : 6718 - 6725 , 1999 ;). the chimeric receptor is made up of the dna binding domain ( dbd ) of yeast gal - 4 or mammalian glucocorticoid receptor ( gr ) transcription factors and the lbd of a mammalian or other pparδ ( β ). in the reporter gene vector , a low expressing promoter ( such as , but not limited to , thymidine kinase or sv - 40 minimal early promoter ) is coupled to a gal - 4 or gr dna response element or multiple copies thereof , and will direct the expression of secreted alkaline phosphatase ( seap ), β - lactamase , or luciferase and / or another suitable reporter gene . according to this cell - based assay , the chimeric receptor binds to the dna response element in the promoter through the gal - 4 or gr dbd and regulates expression of the reporter gene as a function of binding of a ligand ( s ) to the pparδ ( β ) lbd . compounds that inactivate ( antagonists ) or activate ( agonists ) reporter gene expression will be selected on the basis of this assay for further biological testing . in another approach , any established cell line that maintain expression of endogenous pparδ ( β ) are transfected with the pparδ ( β ) selective dna response element ( the ppre ), a directed reporter gene ( such as but not limited to ) seap , β - lactamase or luciferase ( see he et al ., cell , 99 : 335 - 345 , 1999 ; mano et al ., j . biol . chem ., 275 : 8126 - 8132 , 2000 ). in this cell - based assay , the endogenous pparδ ( β ) will bind to the pparδ ( β ) ppre on the promoter and regulate expression of the reporter gene as a function of ligand binding to the pparδ ( β ) lbd . compounds that inactivate ( antagonists ) or activate ( agonists ) will be selected on the basis of this assay for further biological testing . most pre - adipocyte cells ( cultured cells ) and human , primate and rodent primary adipocytes are capable of differentiating into mature adipocytes after induction by hormones and pharmaceutical agents . these hormones and agents may include ( but are not limited to ) insulin , dexamethasone , 3 - isobutyl - 1 - methyl - xanthine ( ibmx ), long chain fatty acids , thiazolidinediones , prostaglandins , leukotrienes , eicosanoids , retinoids , rxrα agonists and any suitable combinations of all of the above ( kohanski et al ., j . biol . chem ., 261 : 12272 - 12281 , 1986 ; brun et al ., genes . dev ., 10 : 974 - 984 , 1996 ). the selected pparδ ( β ) regulators ( antagonists ) are further investigated for their ability to mediate pre - adipocyte differentiation into adipocytes as measured by : ( 1 ) triglyceride accumulation , and / or ( 2 ) the expression of various marker genes such as ap2 , adipsin , lipoprotein lipase or fatty acid synthase . candidate pparδ ( β ) antagonist compounds identified through one or more of the in vitro screening assays described above are then administered to well known animal models such as , but not limited to , genetically or diet - induced obese mice ( ob / ob , db / db , kkay , agouti , high fat diet induced obese c57bl / 6 or others ), rats ( fa / fa , zdf , or others ), hamsters ( high fat diet induced obese golden syrian or other suitable strains ) or monkeys ( high fat diet induced obese cynamologous or african green monkey ) ( see york { genetic models of obesity } and sclafani ( dietary models of obesity }, both in obesity , bjorntorp and brodoff eds . jb lippincott company , 1992 ; mcintosh and pederson , mcneill . eds crc press llc , 337 - 398 , 1999 ). alternatively , these animals may also be used as primary screening tools . compounds are administered in a pharmacologically acceptable vehicle to animals by intravenous , subcutaneous or intraportal injection , orally , or mixed with food or water , acutely or over an extended period of time . during the course of the study , various parameters such as water and food consumption , body weight gain and body temperature , are measured . through tail vein bleeding blood is collected and plasma analyzed for glucose , insulin , free fatty acids , triglycerides and cholesterol . the animals are also tested for glucose tolerance and insulin sensitivity . the treated animals may also be scanned as compared to untreated obese animals for improvement in osteoarthritis of the joints . compounds that act to reduce body weight or decrease plasma glucose and lipid levels or show increased glucose tolerance and insulin sensitivity and / or improvement in osteoarthitis of the joints are then selected for further study . the invention described herein also includes pharmaceutically acceptable compositions of a pparδ ( β ) antagonist for synthesis , storage , and delivery to a mammal ( including humans ) for the treatment of obesity and insulin resistance . many assays known to those skilled in the art of molecular biology , biochemistry , genetics , pharmacology and in vivo physiology can be used to screen and discover compounds that regulate pparδ ( β ) activity , regulate pre - adipocyte differentiation and prevent or ameliorate obesity , insulin resistance , and dys - metabolic syndrome . several exemplary assays are disclosed below . a single e . coli colony containing his - tagged pparδ ( β ) lbd ( amino acid 139 - 441 , schmidt et al ., mol . endocrinology , 6 : 1634 - 1641 , 1992 ) expressing plasmid dna is mixed with 3 ml luria broth ( lb ) supplemented with 100 μg / ml antibiotic ampicilin and grown at 37 ° c . pparδ ( β ) lbd protein expression is induced with iptg ( added to 0 . 4 mm final concentration ). bacterial pellet from 1 liter culture is resuspended in 50 ml of buffer containing 20 mm hepes ( ph 7 . 8 ), 100 mm nacl , 1 mm dtt and 1 complete ™ protease inhibitor cocktail tablet ( boehringer mannheim ) and lysed by sonication . the lysate is centrifuged at 10 , 000 rpm for 30 minutes and the supernatant is used for ligand binding assay . for each binding assay point in a 96 well plate , 37 μg bacterial lysate is mixed with 50 nm of a 3 h - labeled pparδ ( β ) selective ligand ( compound f in leibowitz and berger , wo 97 / 28149 , 1997 ; l - 165041 in berger et al . j . biol . chem . 274 : 6718 - 6725 , 1999 ) in a buffer containing 20 mm tris - hcl ( ph 8 . 0 ), 150 mm nacl , 0 . 5 % bsa , and 0 . 5 % chaps and 333 μg yttrium silicate copper his - tag spa beads ( amersham ) and incubated in a packard 96 well optiplate . non - radiolabeled l - 165041 in dmso solution is added to a desired final concentration to the reaction buffer and further incubated at room temperature for 1 hour . the plates are then read on packard top - count beta - scintillation counter ( 1 minute / well ). the binding affinity of l - 165041 to pparδ ( β ) lbd is determined by calculating the amount of compound required for half maximal ( ic50 = 0 . 052 μm ) inhibition / displacement of 3 h labeled pparδ ( β ) ligand ( compound f in leibowitz and berger , wo 97 / 28149 , 1997 ) binding to pparδ ( β ) protein ( fig3 ). in this binding assay any test compound may replace l - 165041 and the binding affinity for pparδ ( β ) is easily determined . cho cells , stably transfected with a chimeric receptor construct made of yeast gal4 dbd ( amino acid 1 - 144 ; { sadowski and ptashne , nuc . acid . res . 17 : 7539 , 1989 }) fused to human pparδ ( β ) lbd ( amino acid 139 - 441 ; { schmidt et al , mol . endocrinology , 6 : 1634 - 1641 , 1992 }) and a gal4 dna response element ( re ) driven secreted alkaline phosphatase ( seap ) reporter gene is grown in dmem medium supplemented with 10 % fetal calf serum and antibiotics geneticin and zeocin ( 400 μg each ) in 96 well plates . pparδ ( β ) selective agonist l - 165041 is added ( 31600 , 10000 , 1000 , 31 . 6 , 10 , 3 . 16 nm or other suitable concentrations in 0 . 5 % dmso containing media ) to determine dose dependent induction of reporter gene activity in this cell line and pparγ selective ligand brl - 49653 ( lehmann et al ., j . biol . chem . 270 : 12953 - 12956 , 1995 ) is used as a negative control . as illustrated in fig4 l - 165041 dose dependently induced reporter gene activity while pparγ selective ligand brl - 49653 showed no induction . to this cell based assay test compounds may be added to varying concentrations in presence of l - 165041 . the ability of the test compound to competitively inhibit ( antagonist ) reporter gene activation by l - 165041 ( half - maximal inhibition of activation , ec50 in μm ) is calculated . in yet another embodiment , the ability of pparδ ( β ) antagonists to regulate differentiation of mouse pre - adipocyte cell lines such as nih 3t3 - l1 into mature adipocytes and accumulate lipids in the form of triglycerides in presence of hormonal signals may be determined . as an example , 1 . 0 × 10 4 3t3 l1 cells per well are plated and grown to confluency in a 24 well plate in dmem - high medium and 10 % fetal bovine serum . cells are induced to differentiate for 48 hr after adding hormonal cocktail ( 1 μm dexamathasone , 5 μg / ml insulin , and 0 . 6 μm ibmx { kohanski et al ., j . biol . chem . 261 : 12272 - 12281 , 1986 ; brun et al ., genes . dev . 10 : 974 - 984 , 1996 }) to the medium . at this time , agents that further induce differentiation such as brl - 49653 , a proven pparγ agonist ( lehmann et al ., j . biol . chem . 270 : 12953 - 12956 , 1995 ), is added ( 0 . 01 to 10 μm or other suitable concentrations in 0 . 5 % dmso containing media ) into each well . after 24 - 72 hours cells are washed with pbs and lysed in 100 μl pbs containing 1 % triton per well for 20 min . at room temperature . triglyceride content is determined in cell lysates using triglyceride reagent test kit in a cobas - mira instrument . as illustrated in ( fig5 ) brl - 49653 induced significant triglyceride accumulation in cells indicating induction of differentiation . this pre - adipocyte differentiation assay can be easily adapted to test for the ability of pparδ ( β ) antagonists to regulate differentiation and triglyceride accumulation induced by hormonal cocktail and or brl - 49653 . in another preferred embodiment of the present invention c57bl / 6 mice are fed a diet rich in fat ( 40 %) and sucrose ( 40 %) ( see , york { genetic models of obesity } and sclafani ( dietary models of obesity }, both in obesity , bjorntorp and brodoff eds . j b lippincott company , 1992 ; mcintosh and pederson ; mcneill . eds . crc press llc , 337 - 398 , 1999 ; farrelly et al ., proc . natl . acad . sci . 96 : 14511 - 14516 , 1999 ). under these dietary conditions , c57bl / 6 mice gain considerable body weight ( fig6 ) and become obese . these mice may be treated with pparδ ( β ) antagonists ( dose 1 to 100 mg / kg / day ), administered in a pharmacologically acceptable vehicle ( e . g . but not limited to 5 % cm - cellulose ) through intravenous , subcutaneous or intraportal injection , orally , or mixed with food or water , acutely or over an extended period of time . during the course of the study , various parameters such as water and food consumption , body weight gain , body temperature is measured by standard methods . through tail vein bleeding , blood is collected in heparin - edta coated tubes to prevent clotting and blood plasma was separated and analyzed for glucose , free fatty acids , triglycerides and cholesterol using reagent kits available from roche diagnostics in a cobas - mira instrument . insulin and leptin are measured by commercially available elisa kits . the animals are also tested for glucose tolerance and insulin sensitivity . this is performed by injecting a pre - determined dose of insulin ( 0 . 5 units / kg in saline ) or glucose ( 1 gm / kg in saline ) and changes in glucose levels are monitored by tail vein bleed every 30 minutes . the compounds that lead to decreased levels of glucose after insulin injection and after a glucose load are considered insulin - sensitizing glucose lowering agents . compounds that act to reduce body weight and or decrease glucose ; lipid or show increased glucose tolerance and insulin sensitivity are selected . the treated animals may also be scanned using suitable instruments for improvement in osteoarthritis of the joints . test compounds that prevent or ameliorate obesity , insulin resistance , are also tested in the disease models described above , in combination with an anti diabetic agent such as but not limited to metformin and sulfonylurea and / or a lipid lowering agent such as pparα agonists ( such as , but not limited to fenofibrate and gemfibrozil ) and / or hmg coa reductase inhibitors ( such as , but not limited to pravastatin , lovastatin , simvastatin and atorvastatin ). during the course of the study various parameters such as water and food consumption , body weight gain , body temperature and plasma glucose , insulin , free fatty acids , triglycerides and cholesterol levels are measured . the animals are also tested for glucose tolerance and insulin sensitivity . compounds that act to reduce body weight and or decrease glucose , lipid , or show increased glucose tolerance and insulin sensitivity are selected for further characterization . unless otherwise defined , all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs . although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention , the preferred methods and materials are described herein . all publications , patent applications , patents , and other references mentioned herein are incorporated by reference in their entirety . in addition , materials , methods , and examples are illustrative only and are not intended to be limiting . as used herein , the phrase “ therapeutically effective ” is intended to include an amount of a compound , or an amount of a combination of compounds , claimed effective to inhibit pparδ ( β ) activity and / or treat obesity , insulin resistance and / or hyperlipidemia . as used herein , the term “ prodrug ( s )” is intended to include any covalently bonded carriers which release an active parent drug of the present invention in vivo when such a prodrug is administered to a mammalian subject . prodrugs of the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved , either in routine manipulation or in vivo , resulting in the parent compound . prodrugs include compounds of the present invention wherein a hydroxy , amino , or sulfhydryl group is bonded to any group that , when the prodrug of the present invention is administered to a mammalian subject , it cleaves to form a free hydroxyl , free amino , or free sulfhydryl group , respectively . examples of prodrugs include , but are not limited to , acetate , formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention . as used herein , the phrase “ pharmaceutically acceptable ” is employed to refer to those compounds , materials , compositions and / or dosage forms which are , within the scope of sound medical judgment , suitable for use in contact with the tissues of mammals , including human beings , without excessive toxicity , irritation , allergic response , or other problem or complication commensurate with a reasonable benefit / risk ratio . as used herein , the phrase “ anti - diabetic agent ” refers to a compound that will improve insulin resistance and decrease plasma glucose levels in patients with diabetes . representative compounds within the scope of the present invention include but are not limited to metformin , rosiglitazone , and pioglitazone . as used herein , the phrase “ lipid - lowering agent ” refers to a compound that will lower plasma lipid levels — cholesterol and triglycerides , in patients suffering from hyperlipidemia and / or cardiovascular disease . representative compounds within the scope of the present invention include but are not limited to pravastatin , simvastatin , atorvastatin , and gemfibrozil . as used herein , the phrase “ administered in combination ”, and the terms “ combination ” or “ combined ” when referring to compounds , components , or compositions described herein , means the compounds , components , or compositions are administered concurrently to the mammal being treated . when administered in combination each compound , component , or composition may be administered in any order at the same time or sequentially in any order or at different points in time , so as to provide the desired therapeutic effect . as used herein the terms “ modulate or modulates ” refer to an increase or decrease in the amount , quality or effect of a particular activity or protein . a suitable pparδ ( β ) antagonist compound can be administered to patients to treat obesity and other metabolic disorders as the compound alone and / or mixed with an acceptable carrier in the form of pharmaceutical formulations . those skilled in the art of obesity , insulin resistance and hyperlipidemia can easily determine the dosage and route of administration of the compound to mammals , including humans , in need of such treatment . the route of administration may include but is not limited to oral , rectal , transdermal , buccal , subcutaneous , intramuscular , intradermal , intravenouos , or intestinal administration . the compound is formulated according to the route of administration based on acceptable pharmacy practice ( fingl et al ., in the pharmacological basis of therapeutics , ch . 1 , p . 1 , 1975 ; remington &# 39 ; s pharmaceutical sciences , 18 th ed ., mack publishing co , easton , pa ., 1990 ). in combination therapy , the dose and route of administration of the second or third drug ( anti - diabetic or lipid lowering drugs ) will depend on the drug chosen and the severity of insulin resistance , type 2 diabetes and / or hyperlipidemia . the pharmaceutically acceptable pparδ ( β ) antagonist composition of the present invention can be administered in such oral dosage forms as tablets , capsules ( each of which includes sustained release or timed release formulations ), pills , powders , granules , elixirs , tinctures , suspensions , syrups , and emulsions . the composition of the present invention can also be administered in intravenous ( bolus or infusion ), intraperitoneal , subcutaneous , or intramuscular form , all using dosage forms well known to those of ordinary skill in the pharmaceutical arts . the composition may be administered alone , but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice . the dosage regimen for the composition of the present invention will , of course , vary depending upon known factors , such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration ; the species , age , sex , health , medical condition , and weight of the recipient ; the nature and extent of the symptoms ; the kind of concurrent treatment ; the frequency of treatment ; the route of administration , the renal and hepatic function of the patient , and the effect desired . a physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent , counter , or arrest the progress of the disease state . by way of general guidance , the daily oral dosage of the active ingredient , when used for the indicated effects , will range between about 0 . 001 to 1000 mg / kg of body weight , preferably between about 0 . 01 to 100 mg / kg of body weight per day , and most preferably between about 1 . 0 to 20 mg / kg / day . intravenously , the most preferred doses will range from about 1 to about 10 mg / kg / minute during a constant rate infusion . the composition of this invention may be administered in a single daily dose , or the total daily dosage may be administered in divided doses of two , three , or four times daily . the composition of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles , or via transdermal routes , using transdermal skin patches . when administered in the form of a transdermal delivery system , the dosage administration will , of course , be continuous rather than intermittent throughout the dosage regimen . the composition is typically administered in a mixture with suitable pharmaceutical diluents , excipients , or carriers ( collectively referred to herein as pharmaceutical carriers ) suitably selected with respect to the intended form of administration , that is , oral tablets , capsules , elixirs , and syrups , and consistent with conventional pharmaceutical practices . for instance , for oral administration in the form of a tablet or capsule , the active drug component can be combined with an oral , non - toxic , pharmaceutically acceptable , inert carrier such as lactose , starch , sucrose , glucose , methyl cellulose , magnesium stearate , dicalcium phosphate , calcium sulfate , mannitol , and sorbitol ; for oral administration in liquid form , the oral drug components can be combined with any oral , non - toxic , pharmaceutically acceptable inert carrier such as ethanol , glycerol , and water . moreover , when desired or necessary , suitable binders , lubricants , disintegrating agents , and coloring agents can also be incorporated into the mixture . suitable binders include starch , gelatin , natural sugars such as glucose or beta - lactose , corn sweeteners , natural and synthetic gums such as acacia , tragacanth , or sodium alginate , carboxymethylcellulose , polyethylene glycol , and waxes . lubricants used in these dosage forms include sodium oleate , sodium stearate , magnesium stearate , sodium benzoate , sodium acetate , and sodium chloride . disintegrators include , but are not limited to , starch , methyl cellulose , agar , bentonite , and xanthan gum . the composition of the present invention may also be administered in the form of liposome delivery systems , such as small unilamellar vesicles , large unilamellar vesicles , and multilamellar vesicles . liposomes can be formed from a variety of phospholipids , such as cholesterol , stearylamine , or phosphatidylcholines . since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals ( i . e ., solubility , bioavailability , manufacturing , etc .) the compounds of the present invention may be delivered in prodrug form . thus , the present invention is intended to cover prodrugs of the presently claimed compounds , methods of delivering the same and compositions containing the same . the compositions of the present invention may also be coupled with soluble polymers as targetable drug carriers . such polymers can include polyvinyl - pyrrolidone , pyran copolymer , polyhydroxypropyl - methacrylamide - phenol , polyhydroxyethylaspartamidephenol , or polyethyleneoxide - polylysine substituted with palmitoyl residues . furthermore , the composition of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug , for example , polylactic acid , polyglycolic acid , copolymers of polylactic and polyglycolic acid , polyepsilon caprolactone , polyhydroxy butyric acid , polyorthoesters , polyacetals , polydihydropyrans , polycyanoacylates , and crosslinked or amphipathic block copolymers of hydrogels . dosage forms ( pharmaceutical compositions ) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit . in these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0 . 5 - 95 % by weight based on the total weight of the composition . gelatin capsules may contain the active ingredient and powdered carriers , such as lactose , starch , cellulose derivative , magnesium stearate , and stearic acid . similar diluents can be used to make compressed tablets . both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours . compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere , or enteric coated for selective disintegration in the gastrointestinal tract . liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance . in general , water , a suitable oil , saline , aqueous dextrose ( glucose ), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions . solution for parenteral administration preferably contain a water soluble salt of the active ingredient , suitable stabilizing agents , and if necessary , buffer substances . antioxidizing agents such as sodium bisulfite , sodium sulfite , or ascorbic acid , either alone or combined , are suitable stabilizing agents . also used are citric acid and its salts and sodium edta . in addition , parenteral solutions can contain preservatives , such as benzalkonium chloride , methyl - or propyl - paraben , and chlorobutanol . suitable pharmaceutical carriers are described in remington : the science and practice of pharmacy , nineteenth edition , mack publishing company , 1995 , a standard reference text in this field representative useful pharmaceutical dosage forms for administration of the compound of this invention can be illustrated as follows : a large number of unit capsules can be prepared by filling standard two - piece hard gelatin capsules with 100 milligrams of powdered active ingredient , 150 milligrams of lactose , 50 milligrams of cellulose , and 6 milligrams magnesium stearate ; a mixture of active ingredient in a digestable oil such as soybean oil , cottonseed oil or olive oil may be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient . the capsules should be washed and dried . tablets may be prepared by conventional procedures so that the dosage unit , for example is 100 milligrams of active ingredient , 0 . 2 milligrams of colloidal silicon dioxide , 5 milligrams of magnesium stearate , 275 milligrams of microcrystalline cellulose , 11 milligrams of starch and 98 . 8 milligrams of lactose . appropriate coatings may be applied to increase palatability or delay absorption . a parenteral composition suitable for administration by injection may be prepared by stirring 1 . 5 % by weight of active ingredient in 10 % by volume propylene glycol and water . the solution should be made isotonic with sodium chloride and sterilized . an aqueous suspension can be prepared for oral administration so that , for example , each 5 ml contains 100 mg of finely divided active ingredient , 20 mg of sodium carboxymethyl cellulose , 5 mg of sodium benzoate , 1 . 0 g of sorbitol solution , u . s . p ., and 0 . 025 ml of vanillin or other palatable flavoring . obviously , numerous modifications and variations of the present invention are possible in light of the above teachings . it is therefore understood that within the scope of the appended claims , the invention may be practiced otherwise than as specifically described herein . the present invention is not to be limited in scope by the specific embodiments described that are intended as single illustrations of individual aspects of the invention . functionally equivalent methods and components in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings . such modifications are intended to fall within the scope of the appended claims .
obesity is a common clinical problem in most developed nations and is also rapidly becoming a major health concern in developing nations . overweight individuals frequently suffer from several metabolic disorders such as insulin resistance , type 2 diabetes and dyslipidemia . this invention discloses proof of principle for the role pparδ plays in the development of diet - induced obesity . in accordance with the present invention , a new method for treating obesity , insulin resistance and hyperlipidemia through administration of a pharmaceutical composition containing a chemical agent that antagonizes the function of pparδ protein , decreases pparδ gene expression and or transactivation of pparδ target gene expression is disclosed . this invention also proposes that obese , insulin resistant hyperlipidemic patients can be effectively treated with a combination of a pparδ antagonist with either an anti - diabetic agent or a lipid - lowering agent .